Introduction
Epidemiological study found that bone metastasis was a common complication of breast cancer patients [1] . After metastasized into bone, nociceptors innervating of bone are activated by cancer cells and some factors like nerve growth factor (NGF) [2] , prostaglandin E2 (PGE2) [3] and endothelin [4] which secreted by cancer cells, as well as tumor associated immune cells, osteoblasts, osteoclasts lead bone cancer pain production. But current treatment strategies often can't provide adequate analgesia and cause unacceptable side effects [5] . So further understanding the underlying mechanisms of the development of BCP is important for effectively treating these patients Accumulating evidence suggests that inflammatory factors, like TNF-α, IL-1β and so on, have an important role in the induction and maintenance of chronic cancer pain [6] [7] [8] . After nerve injury or proinflammatory mediators' stimulation, spinal microglia is activated and products a large number of inflammatory factors, and that leads to chronic cancer pain [9] . Thymic stromal lymphopoietin (TSLP) is a master switch for allergic inflammation and promotes primarily type 2 inflammatory responses that as a characteristic of a large number of inflammatory factors production, such as TNF-α and IL-1β [10] [11] [12] . Recently studies found that TSLP could activate neurons to induce itch [13] and had a high expression in cancer cells [14, 15] . However, whether TSLP play a role in BCP is unknown.
In this study, we used neutralizing antibody of TSLP to treat MDA-MB-231 cell inoculation-induced BCP model and examined TSLP levels in the intramedullary space of the right femur of model. We also constructed BCP model used MDA-MB-231 cell with the TSLP expression knockdown and examined inflammatory factors levels in the intramedullary space of the right femur of this model.
Methods
Cell culture and generation of stable cell lines shRNA-vectors targeting TSLP were purchased from GenePharma (Shanghai, China) and transfected into cells using Lipofectamine 2000 (Invitrogen, USA) [16] .
Animals and tumor inoculation
Adult (8 weeks same amount of PBS [17] .
Behavioral analysis
Behavioral analysis was performed as described previously [17, 18] . ELISA 20μl 0.9% physiological saline was injected in intramedullary space of the right femur of rats with a 30 G needle and about 15μl lavage fluid was collected for ELISA. Human TSLP, TNF-α, IL-1β, IL-6, CCL2, CXCL2 and CXCL5 ELISA kit was purchased from R&D. ELISA was performed according to manufacturer's protocol. The standard curve was included in each experiment.
Western blot
Western blot studies were performed as described previously [16, 19] . The antibodies were shown as 
Statistical analysis
Statistical analysis was performed as described previously [17] . A value of P<0.05 was considered to indicate a statistically significant difference in all statistical analyses. inoculation, the PWL and PWT were partly attenuated, and maintained to day 28 ( fig.1A and B) .
Result
Meantime, we found that the TSLP levels was not significant change between day 0 and day 28 in Sham animals, but significantly increased at day 28 of MDA-MB-231 cells inoculation which were regulated with intrathecally injection of TSLP neutralizing antibody ( fig.1C ). These data suggest TSLP is involved in tumor cell inoculation-induced pain hypersensitivity. 
MDA-MB-231 cell inoculation induced pain hypersensitivity by releasing TSLP
To check whether the increased TSLP of the intramedullary space of the right femur of mice was released by breast cancer cells, the TSLP protein of normal breast epithelium (MCF-10A) and breast cancer cell lines (BT-474, T-470, MCF-7, ZR-75-30, BT549 and MDA-MB-231) was examined. As shown in fig.2A , we found that the expression of TSLP protein was higher levels in breast cancer cell lines than that in MCF-10A. On the line with that, the TSLP secretion of breast cancer cell lines also was more than MCF-10A ( fig.2B ). Moreover, when MDA-MB-231 cells with TSLP knockdown were inoculation to mics, the TSLP levels of the intramedullary space lavage fluid were obviously decreased ( fig.2C ) and MDA-MB-231 cell inoculation induced pain hypersensitivity was significantly alleviated ( fig.2C and D) . These data indicated that the higher levels of TSLP released by breast cancer cells induced pain hypersensitivity. 
Inhibition of TSLP decreased neuroinflammatory factors levels
Accumulating evidence suggests that neuroinflammation has an important role in the induction and maintenance of chronic pain [6] and TSLP is a proinflammatory factor which induced TH2 inflammation [20] . So we further investigated whether TSLP induced and maintained pain hypersensitivity by promoting neuroinflammatory factors production. Elisa shown that the levels of TNF-α, IL-1β, IL-6, CCL2, CXCL2 and CXCL5 were significantly increased in the intramedullary space lavage fluid of the right femur of rats with MDA-MB-231 cells inoculation for 28d ( fig.3 A-F ). But treatment with Neutralizing antibody of TSLP inhibited the increased levels of TNF-α, IL-1β, IL-6, CCL2, CXCL2 and CXCL5 compared with MDA-MB-231 cells inoculation that without treatment. Moreover, inoculation with MDA-MB-231 cells that TSLP was knockdown, the increased levels of TNF-α, IL-1β, IL-6, CCL2, CXCL2 and CXCL5 were significantly suppressed. These data illustrated that TSLP induced chronic pain by promoting neuroinflammatory factors levels production. vs. 28d Tumor group. &P <0.01 vs. 28d Tumor shNC group. n = 6 mice per group.
Discussion
The data presented herein demonstrate that TSLP was significant increase in the intramedullary space lavage fluid of the right femur after cancer cell inoculation. Inhibition of TSLP or cancer cell with TSLP knockdown attenuated inoculation-induced pain hypersensitivity.
Our data also shows that some inflammatory factors, TNF-α, IL-1β, IL-6, CCL2, CXCL2 and CXCL5, which could induction and maintenance of chronic cancer pain, were significantly elevated in the intramedullary space lavage fluid of the right femur after cancer cell inoculation, but were obviously reduced in models with neutralizing antibody of TSLP treatment and TSLP knockdown. These data suggest that TSLP which secreted by cancer cell plays an important role in the induction and maintenance of BCP via promoting production of inflammatory factors.
TSLP is an important cytokine to regulate Th2 inflammation [20] and induce an abundant inflammatory factors secretion. Recent research findings that TSLP acts directly on a subset of TRPA1-positive sensory neurons to trigger robust itch behaviors in atopic dermatitis [13] . In our studies, we also found that inhibition of TSLP attenuated inoculation-induced pain hypersensitivity.
These data indicated that TSLP play an important role in sensation of peripheral nervous.
However, what secret the increased TSLP in the intramedullary space lavage fluid of the right femur after cancer cell inoculation. Recent studies have also implicated cancer tissue TSLP expression and serum TSLP level were significantly increased [15, 21] . Moreover, the role of TSLP in tumor growth and metastasis is supported by many studies [14, 22, 23] . Consistent with these studies, we found that breast cancer cell lines have more expression and secretion than normal breast epithelium. In addition, TSLP content was also significant increase in the intramedullary space lavage fluid of the right femur after cancer cell inoculation, but the TSLP content was reduced in cancer cell with TSLP knockdown. All these suggested that breast cancer cells released an abundant TSLP to the intramedullary space lavage fluid of the right femur after cancer cell inoculation.
It is increasingly recognized that inflammatory mediators in the peripheral and central nervous system have a key role in the induction and maintenance of chronic pain [6] . Nociceptor neurons express the receptors include GPCRs, ionotropic receptors, and tyrosine kinase receptors， for all these inflammatory mediators, which act on their respective receptors on peripheral nociceptor nerve fibers and causes hypersensitivity and hyperexcitability of nociceptor neurons [24, 25] . We also found that many inflammatory mediators, like TNF-α, IL-1β, IL-6, CCL2, CXCL2
and CXCL5 were significantly increased in space lavage fluid of tumor models, but were obviously reduced in models with neutralizing antibody of TSLP treatment and TSLP knockdown.
These data suggested that TSLP may promote inflammatory mediators' production to induce BCP.
In this study, we found that inoculation of MDA-MB-231 cells into mouse femur induced bone pain hypersensitivity and chemokine TSLP was increased in the intramedullary space lavage fluid of femur. In association with these changes, Inhibition of TSLP or cancer cell with TSLP knockdown attenuated inoculation-induced pain hypersensitivity. Moreover, some increased inflammatory factors, which could induction and maintenance of chronic cancer pain, were significantly reduced in models with neutralizing antibody of TSLP treatment and TSLP knockdown. Our data suggest that TSLP-mediated inflammatory factors release contributes to the maintenance of tumoral hypersensitivity. TSLP may serve as a novel target for the treatment of metastatic breast cancer-induced BCP.
